Table 1 Characteristics of patients with JIA and controls
Oligo JIA (n = 30) | Poly JIA (n = 30) | P-value oligo vs poly JIA | JIA total (n = 60) | Controls (n = 60) | P-value JIA total vs controls | |
|---|---|---|---|---|---|---|
Age (yrs) | 13.5 (2.2) | 13.7 (2.2) | 0.62 | 13.6 (2.2) | 13.5 (2.6) | 0.86 |
Female sex, n (%) | 27 (90) | 23 (77) | 0.17 | 50 (83) | 50 (83) | 1.00 |
Height (cm) | 157.1 (11.8) | 158.7 (13.6) | 0.64 | 157.9 (12.6) | 161.2 (12.6) | 0.16 |
Weight (kg) | 47.0 (10.1) | 51.5 (16.2) | 0.21 | 49.3 (13.8) | 53.5 (15.4) | 0.12 |
BMI (kg/m2) | 18.8 (2.1) | 20.1 (4.4) | 0.17 | 19.4 (3.5) | 20.2 (3.5) | 0.26 |
NRS current pain (0–10), n (%) with score > 0 | 12 (40) | 11 (37) | 0.76 | 23 (38) | 18 (30) | 0.34 |
NRS pain previous week (0–10) | 0.0 (2.0–3.3) | 1.0 (0.0–3.5) | 0.58 | 1.0 (0.0–3.0) | 1.0 (0.0–3.0) | 0.67 |
NRS fatigue previous week (0–10) | 3.5 (2.0–6.3) | 3.0 (2.0–5.3) | 0.61 | 3.0 (2.0–6.0) | 3.0 (1.0–3.5) | 0.09 |
CRP > 4 mg/l, n (%) | 1 (3) | 2 (7) | 1.00 | 3 (5) | 0 (0) | 0.24 |
Physiotherapy regularly, n (%) | 3 (10) | 10 (33) | 0.03 | 13 (22) | 4 (7) | 0.04 |
Disease duration (yrs) | 7.6 (3.9) | 7.3 (4.0) | 0.74 | 7.5 (3.8) | NA | |
JADAS 71 (0–101) | 3.3 (0.8–4.8) | 3.2 (1.4–4.6) | 0.80 | 3.3 (1.1–4.8) | NA | |
CHAQ (0–3) | 0.1 (0.0–0.3) | 0.0 (0.0–0.4) | 0.62 | 0.0 (0–1.4) | NA | |
Off medication, n (%) | 10 (33) | 2 (7) | 0.02 | 12 (20) | NA | |
NSAIDs regularly, n (%) | 9 (30) | 7 (23) | 0.56 | 16 (27) | NA | |
Synthetic DMARDs, n (%) | 18 (60) | 22 (73) | 0.27 | 40 (67) | NA | |
MTX, n (%) | 17 (57) | 21 (70) | 0.28 | 38 (63) | NA | |
Sulfasalazine, n (%) | 1 (3) | 1 (3) | 1.00 | 2 (3) | NA | |
Biologic DMARDs, n (%) | 5 (17) | 20 (67) | < 0.001 | 25 (42) | NA | |
TNFi, n (%) | 5 (17) | 18 (60) | 0.001 | 23 (38) | NA | |
IL-6i, n (%) | 0 (0) | 2 (7) | 0.49 | 2 (3) | NA | |
Synthetic+biologic DMARDs, n (%) | 5 (17) | 14 (47) | 0.01 | 19 (32) | NA | |
Active disease, n (%) | 18 (60) | 22 (73) | 0.27 | 40 (67) | NA | |
Clinical inactive disease, n (%) | 12 (40) | 8 (27) | 20 (33) | NA |